Lasofoxifene tartrate is under clinical development by Ligand Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lasofoxifene tartrate’s likelihood of approval (LoA) and phase transition for Metastatic Breast Cancer took place on 19 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lasofoxifene tartrate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lasofoxifene tartrate overview

Lasofoxifene tartrate (Fablyn) is a potent, nonsteroidal, tissue-selective estrogen receptor modulator (SERM). It was formulated as film-coated tablets for oral route of administration. Fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

It is under development for the treatment of ER+/HER2- metastatic breast cancer as a oral formulation and for vulvovaginal atrophy as a topical gel formulation. It was also under development for the treatment of inflammation, metabolic disorders, vulvovaginal atrophy (VVA) and post menopausal osteoporosis in the US for oral formulation.

Ligand Pharmaceuticals overview

Ligand Pharmaceuticals (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include formulation science, structure-based drug design, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing approval for prescription drugs. Its technologies and research capabilities contributed to the development of a diversified portfolio of biotechnology and pharmaceutical products for the inflammatory, respiratory central nervous system, oncology, ophthalmology, hematology, musculoskeletal disorder, and osteoporosis, among others. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Quick View Lasofoxifene tartrate LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Lasofoxifene tartrate
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Immunology
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Oncology
  • Women’s Health
Key Developers
Highest Development Stage
  • Withdrawn (Marketed)

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.